United States

People: Calyxt Inc (CLXT.OQ)

CLXT.OQ on NASDAQ Stock Exchange Global Market

1:59pm EDT
Change (% chg)

$0.58 (+3.24%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Voytas, Daniel 

Prof. Daniel F. Voytas, Ph.D., is Chief Science Officer of the company since May 2010. Dr. Voytas graduated summa cum laude from Harvard College in 1984 and received his Ph.D. in genetics from Harvard Medical School in 1990. He is one of our co-founders and one of the inventors of the TALEN technology. He continues to optimize the use of TALEN for the targeted modification of plant genomes. In addition to his role at Calyxt, Dr. Voytas is a professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota (UMN), which he joined in 2008, and Director of the UMN’s Center for Genome Engineering. In 1992, Dr. Voytas joined the faculty at Iowa State University. Prior to this, he conducted postdoctoral research at Johns Hopkins University School of Medicine. Dr. Voytas is an elected Fellow of the American Association for the Advancement of Science.

Basic Compensation

Total Annual Compensation, USD 286,500
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,351,710
Fiscal Year Total, USD 1,638,210

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --